Agreements in clinical studies at German university clinics

Raees Ahmed, Thomas Voigt, Matthias Siegert, Christoph Gerst


The article aims to give an overview of the contractual situation in Germany, which arise in clinical studies. The goal of the authors is to show any potential sponsor of a clinical study, who is interested in cooperation with German partners such as universities or other study sites, what kind of agreements may be expected and to give a brief overview about necessary themes included within the contractual negotiations. The different contractual settings are considered from the perspective each different type of agreement. The authors have chosen amongst all possible types the ones which are the most common in a clinical study, such as CDA, MTA, grant agreement, clinical study agreement, CRO-service agreement etc. The authors show the complexity of the contractual setting of a clinical study and emphasize to pay close attention to the contractual settings. Even though the content of the agreement is mostly universal in nature, in some cases, Germany has some very special rules (e.g. regarding employees’ inventions), which any potential sponsor should keep in mind.


Clinical trials, Clinical studies, Agreement, CDA, MTA, Grant agreement, Clinical study agreement, Services agreement

Full Text:



Dieners/Reese, Handbuch des Pharmarechts. 1st ed. Beck Muenchen; 2010.

Deutschland: Weltweite Nr. 3 bei klinischen Studien der Industrie.; Available at: Accessed 26 February 2020.

Wille M, Kleinke S. Klinische Pruefungen von Arzneimitteln an einer deutschen Hochschule: Was ist bei der Gestaltung des Pruefarztvertrages zu beachten? Pharm R. 2004;8:300-8.

Stief/Bromm, Vertragshandbuch Pharma und Life Sciences. 1st ed. C. H. Beck; 2015.

Weitnauer/Mennenoeh, Life Sciences Agreements in Germany. 1st ed. C. H. Beck; 2014.

Jung/Schuebel, Vertraege für Klinische Studien nach AMG und MPG. 1st ed. C. F. Mueller Verlag; 2011.

Bulicz J, Fritzsch D. Pruefer-Initiierte-Studien (Nichtkommerzielle klinische Pruefungen) in Deutschland – Juristische Verantwortlichkeiten und strafrechtsrelevante Haftungsaspekte des pharmazeutischen Unternehmers. Pharm R, 2011;10:401-8.

Festel G. Outsourcing chemical synthesis in the drug discovery process. Drug Discov Today. 2011;16(5-6):237-43.

Bundesverband Medizinischer Auftragsinstitute e.V.; Available at: Accessed 26 February 2020.

Koordinierungszentren für Klinische Studien. Available at: Accessed 26 February 2020.

European Clinical Research Infrastructure Network. Available at: Accessed 26 February 2020.